Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAB122 in Amyotrophic Lateral Sclerosis (ALS)
2020-003376-40Phase 3Completed
- Sponsor
- Ferrer
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing FAB122 (edaravone) 100 mg with Placebo (2 arms). Primary endpoint: Change from baseline in ALSFRS-R score at 48 weeks. Started Jun 2021; status: completed.
02
Drugs
edaravone
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2020-003376-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003376-40.